Labaton Sucharow served as co-lead counsel in this lawsuit filed on behalf of a class of consumers and businesses that purchased TriCor, a cholesterol-fighting prescription drug manufactured and marketed by defendants Abbott Laboratories and French pharmaceutical companies Fournier Industrie et Sante and Laboratoires Fournier.
Plaintiffs allege that, between April 9, 2002 and May 8, 2009, defendants unlawfully monopolized the market by changing the formulation of Tricor in an attempt to keep generic competition out of the market. The case is pending before the Honorable Sue L. Robinson in the District of Delaware.
On October 28, 2009, the court granted final approval to a $65.7 million settlement that ended the litigation. For additional information about the settlement please visit www.tricorsettlement.com.
Useful Links
Our Locations
New York
140 Broadway
New York, NY 10005
212-907-0700
Delaware
300 Delaware Avenue, Suite 1340
Wilmington, DE 19801
302-573-2540
Useful Links
Washington, D.C.
1050 Connecticut Avenue, NW, Suite 500
Washington, D.C. 20036
202-772-1880
The materials appearing on this website are provided for informational purposes only and do not constitute legal advice. You should not take action based upon this information without consulting legal counsel. This site is not intended to create an attorney-client relationship. The hiring of a lawyer is an important decision that should not be based solely upon any single source of information, including advertising on this website. You may ask us to send you further information about us, and we urge you to review other sources of information about us.